Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.40 (54.12% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$30.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
7/27/2016Q216($0.22)$0.01$36.03 million$36.02 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011($0.02)$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateHeadline
07/27/16 07:37 PMVanda Pharmaceuticals : reports 2Q loss
07/27/16 07:37 PMVanda Pharmaceuticals Reports Second Quarter 2016 Financial Results
07/27/16 07:37 PMVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - Earnings Call Transcript
07/27/16 04:45 PMVanda reports 2Q loss -
07/27/16 06:07 AMQ2 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close -
07/22/16 06:59 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:31 PMEquity Roundup: Stock Performance Focus on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
07/20/16 08:14 PMVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Shorted Shares Decreased By 3.15% - Consumer Eagle
07/20/16 08:14 PMWere Analysts Bullish Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) This Week? - Press Telegraph
07/18/16 06:26 AMStock in Positive Territory for the Quarter: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Engelwood Daily
07/17/16 06:32 PMNext Weeks Broker Price Targets For Vanda Pharmaceuticals Inc. (VNDA) - Fiscal Standard
07/16/16 06:26 PMShares Moving Down on the Week: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Engelwood Daily
07/16/16 06:26 PMVenbio Select Advisor LLC Decreased Stake in Vanda Pharmaceuticals INC (NASDAQ:VNDA) by $3.25 Million as ... - Consumer Eagle
07/16/16 10:18 AMShares Experiencing a Downtrend: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - TGP
07/16/16 10:18 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Quarterly Accounts Payable At $22.664 Millions - RealistInvestor.com
07/15/16 06:08 PMTrading Performance and Target Watch for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
07/15/16 06:08 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 07:28 PMVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Short Interest Decreased By 3.15% - Consumer Eagle
07/13/16 07:28 PMVanda Pharmaceuticals Inc Realized Volatility Hits Elevated Level - CML News
07/12/16 03:43 PMVanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016 - [at noodls] - WASHINGTON, July 12, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July 27, 2016, after the ...
07/09/16 06:20 PMVenbio Select Advisor LLC Decreased Stake in Vanda Pharmaceuticals INC (NASDAQ:VNDA) by $3.25 Million as ... - Engelwood Daily
07/08/16 09:57 AMCan Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Improve on the Earnings Front? - Engelwood Daily
07/08/16 09:57 AMCompany Stock Focus for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Which Way Will Shares Head? - Press Telegraph
07/05/16 06:44 PMAir T Inc. (NASDAQ:AIRT) Went Down -1.91%: Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), CPFL Energia S.A. ... - KC Register
07/05/16 06:44 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 05:58 AMBroker Outlook For The Week Ahead Vanda Pharmaceuticals Inc. (VNDA) - Fiscal Standard
07/02/16 06:35 PMVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Shorts Decreased by 3.15% After Short Covering - Engelwood Daily
07/02/16 09:41 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Accounts Payable Stands AT $22.664 - RealistInvestor.com
06/30/16 09:50 AMVanda Pharmaceuticals : Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma
06/29/16 07:02 PMNew Broker Ratings For Vanda Pharmaceuticals Inc. (VNDA) - FTSE News
06/29/16 07:02 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Company Rating and Target Watch - Telanagana Press
06/28/16 06:19 AMHow Many Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s Analysts Are Bearish? - Press Telegraph
06/27/16 06:56 PMShare Update and Earnings Review for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
06/27/16 06:19 AMVanda Pharmaceuticals Inc. (VNDA) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 06:28 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Yearly Accounts Payable At $15.767 Millions - RealistInvestor.com
06/25/16 10:47 AMVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Sellers Covered 13.83% of Their Shorts - Engelwood Daily
06/24/16 07:08 PMCovering the Bases on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Where is the Stock Going? - Press Telegraph
06/24/16 07:08 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:00 PMVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/23/16 07:56 PMEquity Research and Technical Review on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
06/23/16 07:56 PMVanda Pharmaceuticals, Inc. (NasdaqGM:VNDA) Stock Momentum Hits Strength - CML News
06/20/16 04:19 PMVanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference - [at noodls] - WASHINGTON, June 20, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation ...
06/19/16 06:19 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Accounts Payable Is $22.664 For The Quarter Ended 2016-03-31 - RealistInvestor.com
06/18/16 06:04 PMTrending Stock Analyst Review: Vanda Pharmaceuticals (NASDAQ:VNDA)
06/17/16 09:49 AMRecently Issued Stock Ratings For Vanda Pharmaceuticals Inc. (VNDA) - Fiscal Standard
06/16/16 04:01 PMVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 07:01 PMFDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia
06/15/16 01:35 PMFDA gives Vanda Pharmaceuticals three-year marketing exclusivity for Fanapt -
06/15/16 08:10 AMVanda Gets FDA Approval For Fanapt Marketing Exclusivity - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) revealed that the U.S. Food and Drug Administration has granted three years of marketing exclusivity for the changes in respect of the supplemental New Drug Application (sNDA), which was ...Full story available on Benzinga.com
06/14/16 10:38 AMHow one investor is staying with Vanda -

Social

About Vanda Pharmaceuticals

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VNDA
  • CUSIP: 92165910
Key Metrics:
  • Previous Close: $11.29
  • 50 Day Moving Average: $11.17
  • 200 Day Moving Average: $9.27
  • P/E Ratio: N/A
  • P/E Growth: -0.81
  • Market Cap: $487.20M
  • Beta: 1.66
  • Current Year EPS Consensus Estimate: $-0.86 EPS
  • Next Year EPS Consensus Estimate: $-0.15 EPS
Additional Links:
Vanda Pharmaceuticals (NASDAQ:VNDA) Chart for Thursday, July, 28, 2016